Report cover image

Global Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors Market Growth 2025-2031

Publisher LP Information, Inc.
Published Nov 13, 2025
Length 139 Pages
SKU # LPI20571844

Description

The global Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

Integrase strand transfer inhibitors stop integrase, a human immunodeficiency virus Type 1 (HIV-1) viral enzyme involved in integrating viral DNA into the host chromosome, from working. For viral replication to take place, the viral DNA must be integrated into the host DNA. Integrase strand transfer inhibitors are used to prevent the human immunodeficiency virus from reproducing in the host and are not a cure for HIV or AIDS.

United States market for Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors players cover Gilead Sciences, Inc, Emcure Pharmaceuticals Limited, Cipla Inc, Hetero, Bausch Health Companies Inc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LP Information, Inc. (LPI) ' newest research report, the “Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors Industry Forecast” looks at past sales and reviews total world Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors sales in 2024, providing a comprehensive analysis by region and market sector of projected Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors sales for 2025 through 2031. With Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors industry.

This Insight Report provides a comprehensive analysis of the global Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors.

This report presents a comprehensive overview, market shares, and growth opportunities of Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Injection
Pill

Segmentation by Application:
Aldult
Child

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Gilead Sciences, Inc
Emcure Pharmaceuticals Limited
Cipla Inc
Hetero
Bausch Health Companies Inc
Johnson & Johnson
Mylan NV
Teva Pharmaceutical Industries Ltd
Sanofi
Novartis AG
Sun Pharmaceutical Industries Ltd
Aurobindo Pharma
Biocon
Bristol-Myers Squibb Company
GlaxoSmithKline plc
Laurus Labs
Flamingo Pharma Limited
Shanghai Desano Pharmaceuticals Co., Ltd

Key Questions Addressed in this Report

What is the 10-year outlook for the global Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors market?

What factors are driving Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors market opportunities vary by end market size?

How does Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.

Table of Contents

139 Pages
1 Scope of the Report
2 Executive Summary
3 Global by Company
4 World Historic Review for Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors by Geographic Region
5 Americas
6 APAC
7 Europe
8 Middle East & Africa
9 Market Drivers, Challenges and Trends
10 Manufacturing Cost Structure Analysis
11 Marketing, Distributors and Customer
12 World Forecast Review for Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors by Geographic Region
13 Key Players Analysis
14 Research Findings and Conclusion

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us